EP1996937A4 - Materiels génétiques et utilisations correspondantes - Google Patents

Materiels génétiques et utilisations correspondantes

Info

Publication number
EP1996937A4
EP1996937A4 EP07752549A EP07752549A EP1996937A4 EP 1996937 A4 EP1996937 A4 EP 1996937A4 EP 07752549 A EP07752549 A EP 07752549A EP 07752549 A EP07752549 A EP 07752549A EP 1996937 A4 EP1996937 A4 EP 1996937A4
Authority
EP
European Patent Office
Prior art keywords
genetic packages
packages
genetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07752549A
Other languages
German (de)
English (en)
Other versions
EP1996937A2 (fr
Inventor
Volker Schellenberger
Willem P Stemmer
Chia-Wei Wang
Michael D Scholle
Mikhail Popkov
Nathaniel C Gordon
Andreas Crameri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amunix Pharmaceuticals Inc
Original Assignee
Amunix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38475542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1996937(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/528,927 external-priority patent/US20070191272A1/en
Application filed by Amunix Inc filed Critical Amunix Inc
Publication of EP1996937A2 publication Critical patent/EP1996937A2/fr
Publication of EP1996937A4 publication Critical patent/EP1996937A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP07752549A 2006-03-06 2007-03-06 Materiels génétiques et utilisations correspondantes Withdrawn EP1996937A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74341006P 2006-03-06 2006-03-06
US74362206P 2006-03-21 2006-03-21
US11/528,927 US20070191272A1 (en) 2005-09-27 2006-09-27 Proteinaceous pharmaceuticals and uses thereof
US11/528,950 US20070212703A1 (en) 2005-09-27 2006-09-27 Proteinaceous pharmaceuticals and uses thereof
PCT/US2007/005857 WO2007103455A2 (fr) 2006-03-06 2007-03-06 Materiels génétiques et utilisations correspondantes

Publications (2)

Publication Number Publication Date
EP1996937A2 EP1996937A2 (fr) 2008-12-03
EP1996937A4 true EP1996937A4 (fr) 2009-04-08

Family

ID=38475542

Family Applications (3)

Application Number Title Priority Date Filing Date
EP07752549A Withdrawn EP1996937A4 (fr) 2006-03-06 2007-03-06 Materiels génétiques et utilisations correspondantes
EP07752636.6A Active EP1996220B2 (fr) 2005-09-27 2007-03-06 Polymères recombinés non structurés et utilisations correspondantes
EP20140189047 Ceased EP2863222A1 (fr) 2006-03-06 2007-03-06 Polymères recombinants non structurés et leurs utilisations

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP07752636.6A Active EP1996220B2 (fr) 2005-09-27 2007-03-06 Polymères recombinés non structurés et utilisations correspondantes
EP20140189047 Ceased EP2863222A1 (fr) 2006-03-06 2007-03-06 Polymères recombinants non structurés et leurs utilisations

Country Status (6)

Country Link
EP (3) EP1996937A4 (fr)
AU (2) AU2007223855B2 (fr)
CA (1) CA2644712C (fr)
DK (1) DK2402754T4 (fr)
SI (1) SI2402754T2 (fr)
WO (2) WO2007103515A2 (fr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060403A2 (fr) 2003-01-06 2004-07-22 Angiochem Inc. Methode de transport d'un compose a travers une barriere sang/cerveau
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
WO2007073486A2 (fr) 2005-12-20 2007-06-28 Duke University Procedes et compositions pour l'administration d'agents actifs a proprietes pharmacologiques ameliorees
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
AU2007223855B2 (en) 2006-03-06 2013-05-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
JP2010536341A (ja) * 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
CN102131516B (zh) 2008-06-27 2016-03-16 杜克大学 包含弹性蛋白样肽的治疗剂
CA2740316A1 (fr) 2008-10-15 2010-04-22 Angiochem Inc. Conjugues d'agonistes de glp-1 et leurs utilisations
CA2745524C (fr) 2008-12-05 2020-06-09 Angiochem Inc. Conjugues de neurotensine ou d'analogues de neurotensine et leurs applications
ES2610356T3 (es) * 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
AU2015218510B2 (en) * 2009-02-03 2016-11-10 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
AU2014206217B2 (en) * 2009-02-03 2015-09-17 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
MX2011011023A (es) 2009-04-20 2012-01-20 Angiochem Inc Tratamiento de cancer de ovarios usando un agente anti-cancer conjugado con un analogo de angiopep-2.
WO2010144508A1 (fr) * 2009-06-08 2010-12-16 Amunix Operating Inc. Polypeptides de régulation du glucose et leurs procédés de production et d'utilisation
KR101813727B1 (ko) * 2009-06-08 2018-01-02 아뮤닉스 오퍼레이팅 인코포레이티드 성장 호르몬 폴리펩타이드 및 이를 제조하고 사용하는 방법
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
RU2012103240A (ru) * 2009-07-02 2013-08-10 Ангиокем Инк. Мультимерные пептидные конъюгаты и их применение
CA2771999A1 (fr) * 2009-08-24 2011-03-10 Amunix Operating Inc. Compositions de facteurs de coagulation vii et procedes de preparation et d'utilisation de celles-ci
EP2502939B1 (fr) * 2009-11-19 2016-01-27 Zhejiang University Protéine non naturelle de type collagène et son utilisation
SI2506868T1 (en) 2009-12-06 2018-04-30 Bioverativ Therapeutics Inc. HYPER AND HYBRID POLYPETTIDES FACTOR VIII-FC AND METHODS FOR THEIR USE
US8557961B2 (en) 2010-04-02 2013-10-15 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
ES2993140T3 (en) * 2010-04-02 2024-12-23 Amunix Pharmaceuticals Inc Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
US9221882B2 (en) 2010-05-21 2015-12-29 Technische Universitat Munchen Biosynthetic proline/alanine random coil polypeptides and their uses
ES2486321T3 (es) 2010-06-18 2014-08-18 Xiberscience Gmbh Péptidos como agentes activos para estabilizar barreras biológicas
PL3552619T3 (pl) 2010-07-09 2025-12-01 Bioverativ Therapeutics Inc. Polipeptydy czynnika ix i sposoby ich zastosowania
PL2643349T3 (pl) 2010-11-26 2020-03-31 Molecular Partners Ag Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
PT3513804T (pt) 2011-07-08 2022-06-02 Bioverativ Therapeutics Inc Polipéptidos fator viii híbridos e quiméricos, e métodos de utilização dos mesmos
WO2013016454A1 (fr) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Dosages pour la surveillance de troubles hémostatiques
CN104271150A (zh) * 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
EP2822577B1 (fr) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Protéines de facteur viii de recombinaison
JP6256882B2 (ja) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
JP6355563B2 (ja) 2012-02-27 2018-07-11 アムニクス オペレーティング インコーポレイテッド Ｘｔｅｎ共役組成物およびそれを製造する方法
ES2753135T3 (es) 2012-05-07 2020-04-07 Allergan Inc Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF
AU2013263349B2 (en) 2012-05-17 2016-09-08 Extend Biosciences, Inc Carriers for improved drug delivery
WO2014001442A1 (fr) 2012-06-28 2014-01-03 Molecular Partners Ag Conception de protéines à motifs ankyrine répétés liées au facteur de croissance dérivé des plaquettes
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
CN104661674A (zh) 2012-07-11 2015-05-27 阿穆尼克斯运营公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
HK1213521A1 (zh) 2012-09-25 2016-07-08 Bioverativ Therapeutics Inc. Fix多肽的應用
EP2738180A1 (fr) 2012-11-30 2014-06-04 Molecular Partners AG Protéines de liaison comportant au moins deux domaines de liaison ciblant HER2
WO2014144549A1 (fr) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Préparations contenant un polypeptide du facteur ix
WO2015022326A1 (fr) 2013-08-12 2015-02-19 Xiber Science Gmbh Peptides en tant qu'agents actifs pour le traitement d'un dysfonctionnement du greffon primaire
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
PT3065761T (pt) 2013-11-05 2020-02-21 Allergan Inc Método de tratamento de condições oculares com um darpin anti-vegf
EP3065769A4 (fr) 2013-11-08 2017-05-31 Biogen MA Inc. Composé de fusion procoagulant
AU2015204646B2 (en) 2014-01-10 2020-08-27 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
WO2015195531A2 (fr) 2014-06-18 2015-12-23 Albert Einstein College Of Medicine, Inc. Polypeptides syntac et leurs utilisations
WO2016065042A1 (fr) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Conjugués de vitamine d thérapeutiques
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
KR102427117B1 (ko) 2015-04-02 2022-07-29 몰리큘라 파트너스 아게 혈청 알부민에 대한 결합 특이성을 갖는 설계된 안키린 반복 도메인
ES2784603T3 (es) 2015-06-02 2020-09-29 Novo Nordisk As Insulinas con extensiones recombinantes polares
EP3307326B9 (fr) 2015-06-15 2021-02-24 Angiochem Inc. Procédés de traitement d'une carcinomatose leptoméningée
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
EP3355931B1 (fr) 2015-10-01 2024-06-26 Novo Nordisk A/S Conjugués de protéines
CN109689096A (zh) 2016-05-18 2019-04-26 阿尔伯特爱因斯坦医学院公司 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法
WO2017201210A1 (fr) 2016-05-18 2017-11-23 Cue Biopharma, Inc. Polypeptides multimères modulateurs des lymphocytes t et leurs procédé d'utilisation
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
ES2973548T3 (es) 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
EP3565829A4 (fr) 2017-01-09 2021-01-27 Cue Biopharma, Inc. Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
JP2020513019A (ja) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
JP2020534352A (ja) 2017-09-07 2020-11-26 キュー バイオファーマ，インコーポレーテッド コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
WO2019201855A1 (fr) * 2018-04-16 2019-10-24 Swedish Orphan Biovitrum Ab (Publ) Protéine de fusion lysosomale
PL3793588T3 (pl) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a
TWI856047B (zh) 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
JP2022522405A (ja) 2019-03-06 2022-04-19 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
EP3935079A4 (fr) 2019-03-06 2023-03-22 Cue Biopharma, Inc. Polypeptides de présentation d'antigènes modulateurs de lymphocytes t et leurs procédés d'utilisation
CA3138805A1 (fr) 2019-06-04 2020-12-10 Johannes Schilling Domaine de repetition d'ankyrine synthetiques avec une stabilite amelioree
JP2023538533A (ja) 2020-08-07 2023-09-08 ブリストル－マイヤーズ スクイブ カンパニー 線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１
CN114729060B (zh) 2020-09-30 2022-11-25 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
US20240123031A1 (en) 2020-11-25 2024-04-18 Bristol-Myers Squibb Company Methods of treating liver diseases
WO2022123459A1 (fr) 2020-12-11 2022-06-16 Friedrich Miescher Institute For Biomedical Research Protéines de liaison à hdac6 et leur utilisation antivirale
EP4323413A4 (fr) 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd Compositions pharmaceutiques liquides de conjugués polypeptidiques et leurs procédés d'utilisation
CN115083016A (zh) * 2022-06-09 2022-09-20 广州紫为云科技有限公司 一种基于单目摄像机的面向小目标手部隔空交互方法与装置
KR20250075704A (ko) 2022-09-30 2025-05-28 익스텐드 바이오사이언시즈, 인크. 장기-지속형 부갑상선 호르몬

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD257197A1 (de) † 1987-01-28 1988-06-08 Univ Dresden Tech Verfahren zur herstellung von immobilisierten, in ihrer biologischen aktivitaet stabilisierten und in ihren pharmakologischen eigenschaften modifizierten insulinpraeparationen
FR2647677B1 (fr) * 1989-05-31 1991-09-27 Roussel Uclaf Nouvelles micro-proteines, procede de preparation et application a titre de medicaments de ces nouvelles micro-proteines
HUT69963A (en) † 1990-12-13 1995-09-28 Upjohn Co Non-naturally-occuring fusion proteins and process for preparing them
US5833911A (en) † 1995-05-31 1998-11-10 Johnson & Johnson Medical, Inc. Method for forming a glove using a folded glove form
AU5065198A (en) † 1996-11-15 1998-06-10 Maria Grazia Masucci Fusion proteins having increased half-lives
EP1054973A1 (fr) * 1998-02-11 2000-11-29 Maxygen, Inc. Immunisation par bibliotheque d'antigenes
US20050260605A1 (en) * 1998-02-11 2005-11-24 Maxygen, Inc. Targeting of genetic vaccine vectors
US20050287153A1 (en) † 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20030049689A1 (en) * 2000-12-14 2003-03-13 Cynthia Edwards Multifunctional polypeptides
US20020169125A1 (en) * 2001-03-21 2002-11-14 Cell Therapeutics, Inc. Recombinant production of polyanionic polymers and uses thereof
BRPI0606934A2 (pt) † 2005-01-25 2017-07-11 Cell Therapeutics Inc Conjugado de proteína biologicamente ativa, composição, molécula de dna quimérica, vetor, célula, e, métodos para preparar conjugado de proteína biologicamente ativa, e para determinar se um dado conjugado de proteína exibe uma meia-vida de plasma modificada comparada com a meia-vida intrínseca do polipeptídeo biologicamente ativo não conjungado
WO2007073486A2 (fr) † 2005-12-20 2007-06-28 Duke University Procedes et compositions pour l'administration d'agents actifs a proprietes pharmacologiques ameliorees
AU2007223855B2 (en) 2006-03-06 2013-05-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
WO2008049711A1 (fr) † 2006-10-27 2008-05-02 Novo Nordisk A/S Insuline à peptide ajouté

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BULAJ GRZEGORZ ET AL: "Efficient oxidative folding of conotoxins and the radiation of venomous cone snails.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 100, no. Supplement 2, 25 November 2003 (2003-11-25), pages 14562 - 14568, XP002515375, ISSN: 0027-8424 *
CHEN X J ET AL: "Site-directed mutations in a highly conserved region of Bacillus thuringiensis delta-endotoxin affect inhibition of short circuit current across Bombyx mori midguts.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 1 OCT 1993, vol. 90, no. 19, 1 October 1993 (1993-10-01), pages 9041 - 9045, XP002515378, ISSN: 0027-8424 *
GOMEZ-DUARTE O G ET AL: "Expression of fragment C of tetanus toxin fused to a carboxyl-terminal fragment of diphtheria toxin in Salmonella typhi CVD 908 vaccine strain", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 13, no. 16, 1 November 1995 (1995-11-01), pages 1596 - 1602, XP004057422, ISSN: 0264-410X *
PI C ET AL: "Analysis of expressed sequence tags from the venom ducts of Conus striatus: focusing on the expression profile of conotoxins", BIOCHIMIE, MASSON, PARIS, FR, vol. 88, no. 2, 1 February 2006 (2006-02-01), pages 131 - 140, XP025066514, ISSN: 0300-9084, [retrieved on 20060201] *

Also Published As

Publication number Publication date
AU2007223888A1 (en) 2007-09-13
EP1996220A2 (fr) 2008-12-03
SI2402754T2 (sl) 2023-09-29
AU2007223855B2 (en) 2013-05-16
EP1996220B2 (fr) 2023-08-16
EP1996937A2 (fr) 2008-12-03
SI2402754T1 (sl) 2015-02-27
CA2644712A1 (fr) 2007-09-13
DK2402754T4 (da) 2023-08-28
EP1996220B1 (fr) 2013-05-08
WO2007103515A2 (fr) 2007-09-13
AU2007223855A1 (en) 2007-09-13
EP2863222A1 (fr) 2015-04-22
DK2402754T3 (en) 2015-01-12
EP1996220A4 (fr) 2009-04-29
WO2007103515A3 (fr) 2008-04-03
CA2644712C (fr) 2016-09-13
WO2007103455A2 (fr) 2007-09-13
WO2007103455A3 (fr) 2007-11-29

Similar Documents

Publication Publication Date Title
EP1996937A4 (fr) Materiels génétiques et utilisations correspondantes
ZA200810323B (en) Fkbp-l and uses thereof
LT2064327T (lt) Dbait ir jų panaudojimas
IL195658A0 (en) Anti-nkg2a antibodies and uses thereof
ZA200902823B (en) Oligoribonucleotides and uses thereof
IL196397A0 (en) Prlr-specific antibody and uses thereof
AU313875S (en) Package
IL194751A0 (en) Drugs and uses
ZA200903906B (en) Carboranylporphyrins and uses thereof
IL196861A0 (en) Antibodies against ccr5 and uses thereof
IL195525A0 (en) Replikin peptides and uses thereof
IL193469A0 (en) Novel lipases and uses thereof
GB0621160D0 (en) Compounds and uses thereof
EP2124908A4 (fr) Composés et utilisations de ceux-ci
EP2120563A4 (fr) Composés et leurs utilisations
EP2027026A4 (fr) Emballage
PL1820741T3 (pl) Opakowanie
EP2099459A4 (fr) Composés et leurs utilisations
GB0604187D0 (en) Peptide and uses thereof
PL2032708T3 (pl) Rekombinowane nowirabdowirusy i ich zastosowania
ZA200807233B (en) Novel lipases and uses thereof
GB0603717D0 (en) Electricity-generate and store
IL192800A0 (en) Fgf2-binding peptides and uses thereof
EP2120957A4 (fr) Composés et leurs utilisations
GB0621665D0 (en) Blogmail and podmail

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081006

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20090305

17Q First examination report despatched

Effective date: 20090717

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AMUNIX OPERATING INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110421